top of page
  • Summer Atlantic

Mr. Sebright Chen, Founder of Summer Atlantic Capital, speaks on Eastern Europe Market Expansion Strategy in BIOCHINA 2024.

On March 14-16, leading pharmaceutical companies globally participated in the international BIOCHINA 2024 convention held in Suzhou, China. This event hosted over 1,800 companies and 30,000 participants, focusing primarily on technology, market, capital, and business development opportunities to foster joint development and innovation in the biopharmaceutical field.

Mr. Sebright Chen, Founder, Chairman and CEO of Summer Atlantic Capital, was the keynote speaker and hosted a session titled "Challenges and Opportunities Encountered by Chinese Pharmaceutical Companies in Tapping Global Markets and How to Utilize the Eastern Europe Region as a Game Changer for Their Global Expansion." He explored the challenges and opportunities for Chinese pharmaceutical companies in global markets, emphasizing the strategic potential of expanding in the Eastern Europe region.

In his presentation, Mr. Chen highlighted important market trends for various pharmaceutical products, including the potential to expand the Active Pharmaceutical Ingredients (API) market as patents for major small-molecule innovative drugs expire in the coming years. He noted that key factors for the profitability of international API sales include generic drug strategies and improving manufacturing processes and technology rather than relying on large-scale manufacturing cost advantages. Intense price competition in the U.S. generic tablet market has limited overall growth, making it difficult to compete with companies from other countries on a cost level. Pseudo-innovative drug globalization has also proven challenging for Chinese companies due to the complex commercialization in the U.S. market. Consequently, Mr. Chen indicated that high-quality biopharmaceutical manufacturing operations will provide a competitive advantage in the industry.

Furthermore, Mr. Chen discussed the complex components and cultural differences of Traditional Chinese Medicine (TCM) and FDA's 2004 Guideline for Botanical Drugs setting specific standards on TCM review. He suggested that restructuring the distribution strategies for these products is necessary for their global expansion.

Mr. Chen outlined several global strategy development challenges, including capital challenges from low government funding, talent challenges related to the challenge of finding skilled personnel to ensure strength in continuous innovation, and regulatory challenges when entering the global market, as drug trial data requires certification and approval by authorities such as FDA and EMA, increasing complexity and potential delays. He also addressed challenges associated with international multi-center clinical trials, such as ensuring ethical practices, data integrity, and quality across multiple locations and countries and coordinating logistics and drug distribution, especially in areas with limited infrastructure.

Mr. Chen discussed possible global expansion strategies such as pursuing joint ventures, selecting the right Contract Research Organization (CRO), and implementing thorough supply chain, talent and market entry strategies. Mr. Chen emphasized how these strategies help overcome local policy barriers, ensure quality for global clinical trials, ensure regulatory compliance, establish reliable partnerships, foster a strong company culture and result in successful international market entry.

The session also featured a panel discussion with industry professionals in the biotechnology and pharmaceutical industries. They shared their knowledge and expertise on expanding into international pharmaceutical markets and provided practical advice for Chinese biopharmaceutical companies seeking to grow their businesses internationally. The discussion addressed several crucial issues, including identifying hurdles, regulatory complexities, market dynamics, and the need for strategic partnerships. Despite these challenges, numerous opportunities for growth and innovation were identified. From tapping into emerging trends in clinical research to exploring collaborative ventures in research and development, the potential for Chinese biotechnology and pharmaceutical companies in the Eastern Europe region is immense. Mr. Chen's session provided Chinese biopharmaceutical companies and viewers a unique opportunity to gain in-depth insight into global market dynamics and trends, explore effective international expansion strategies and learn how to collaborate with companies in the Eastern Europe region as a strategic platform for global expansion.

At the end of this session, Mr. Chen encouraged all participants to reflect on how they can apply these insights in the pharmaceutical industry and seize the opportunities presented by the Eastern Europe region to drive forward the global expansion of Chinese pharmaceutical companies.


bottom of page